NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis $46.80 -1.48 (-3.06%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AxoGen Stock (NASDAQ:AXGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AxoGen alerts:Sign Up Key Stats Today's Range$46.26▼$47.9850-Day Range$38.72▼$51.7352-Week Range$15.27▼$52.91Volume200,681 shsAverage Volume1.08 million shsMarket Capitalization$2.52 billionP/E RatioN/ADividend YieldN/APrice Target$51.56Consensus RatingModerate Buy Company Overview AxoGen, Inc. is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts. The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue. These proprietary platforms are supported by a direct sales force in the United States and strategic distributor partnerships in international markets. AxoGen markets its technologies across North America, Europe, Australia and parts of Latin America, collaborating with surgeons in specialties such as hand, orthopedics, plastic and reconstructive surgery. The company leverages clinical training programs, peer-reviewed research and reimbursement support services to drive adoption of its nerve repair solutions. As it advances its product pipeline, AxoGen continues to seek regulatory clearances and expand its global footprint in the evolving field of peripheral nerve repair.AI Generated. May Contain Errors. Read More AxoGen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreAXGN MarketRank™: AxoGen scored higher than 54% of companies evaluated by MarketBeat, and ranked 464th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingAxoGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAxoGen has a consensus price target of $51.56, representing about 10.5% upside from its current price of $46.66.Amount of Analyst CoverageAxoGen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AxoGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.45) to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -68.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -68.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 16.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.42% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 4.07.Change versus previous monthShort interest in AxoGen has recently decreased by 17.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.10 News SentimentAxoGen has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AxoGen this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for AXGN on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,656,947.00 in company stock.Percentage Held by Insiders2.44% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXGN Stock News HeadlinesAxogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare ConferenceSeptember 1, 2026 | globenewswire.comAxoGen, Inc. (NASDAQ:AXGN) Receives $51.00 Consensus Price Target from AnalystsAugust 29, 2026 | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 8 at 1:00 AM | Porter & Company (Ad)Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100August 26, 2026 | gurufocus.comAmy Mcbride Wendell Sells 13,353 Shares of AxoGen (NASDAQ:AXGN) StockAugust 13, 2026 | insidertrades.comAxogen (AXGN) Q2 2026 Earnings Call TranscriptAugust 8, 2026 | finance.yahoo.comDer aktuelle Kurs der Axogen Inc Aktie beträgt 44,42.August 6, 2026 | de.investing.comAxogen: The Regulatory Moat Is Becoming A Commercial FlywheelAugust 3, 2026 | seekingalpha.comSee More Headlines AXGN Stock Analysis - Frequently Asked Questions How have AXGN shares performed this year? AxoGen's stock was trading at $32.73 on January 1st, 2026. Since then, AXGN stock has increased by 42.5% and is now trading at $46.6550. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) announced its earnings results on Wednesday, July, 29th. The medical equipment provider reported $0.12 EPS for the quarter, missing the consensus estimate of $0.12 by $0.00. The medical equipment provider earned $69.73 million during the quarter, compared to analysts' expectations of $67.10 million. AxoGen had a negative trailing twelve-month return on equity of 8.90% and a negative net margin of 13.36%. Read the conference call transcript. Who are AxoGen's major shareholders? Top institutional shareholders of AxoGen include BlackRock Inc. (8.22%), California State Teachers Retirement System (4.95%), Wellington Management Group LLP (2.59%) and Wasatch Advisors LP (2.44%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Michael D Dale, Peter J Mariani, Marc A Began, Michael Patrick Donovan, Lindsey Marie Hartley, Paul Thomas, John Johnson, Joseph A Tyndall, William P Mr Burke and Kathy Johnson Weiler. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings7/29/2026Today9/08/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 AXGN's financial health is in the Green zone, according to TradeSmith. AXGN has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:AXGN CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees450Year Founded2002Price Target and Rating Average Price Target for AxoGen$51.56 High Price Target$60.00 Low Price Target$40.00 Potential Upside/Downside+10.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.70 million Net Margins-13.36% Pretax Margin-13.36% Return on Equity-8.90% Return on Assets-6.47% Debt Debt-to-Equity Ratio0.07 Current Ratio6.60 Quick Ratio5.04 Sales & Book Value Annual Sales$251.17 million Price / Sales9.99 Cash FlowN/A Price / Cash FlowN/A Book Value$2.79 per share Price / Book16.72Miscellaneous Outstanding Shares53,762,000Free Float52,450,000Market Cap$2.51 billion OptionableOptionable Beta1.16 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:AXGN) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our Partners2:59 PM Friday. I make this trade.Tim Sykes says he books gains almost every weekend using one simple move. The trade is placed around 2:59 p...Tim Sykes | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | Sponsoredstop trying to pick stocksMost traders think their problem is picking better stocks. It's actually time: holding losing positions too lo...TradeWins | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
